Hanall Biopharma Files 2025 Sustainability Report Voluntarily, No Direct Shareholder Value Impact from ESG Disclosures
Hanall Biopharma voluntarily submitted its 2025 Sustainability Report on June 30, 2026, prepared in accordance with GRI Standards 2021.
The report covers environmental management, social responsibility, and governance improvements, with no mention of capital changes or shareholder return policies.
The Korean Foundation for Quality conducted third-party verification on the 2025 data, and financial information is presented under K-IFRS consolidation standards.
[AI Summary]This sustainability report transparently discloses Hanall Biopharma's ESG management status, but contains no capital raising or shareholder return plans, thus no direct impact on shareholder value. However, strengthened ESG activities may positively influence long-term corporate value.
KOSPI Filing Information
Matters Related to Sustainability Management Report, etc. (Voluntary Disclosure)